The preliminary findings of the STROKESTOP trial were presented at the ESC Congress today by Dr Emma Svennberg from Sweden.
Amsterdam, The Netherlands – Saturday 31 August 2013: Mass screening in more than 25,000 Swedish residents has identified untreated atrial fibrillation in 5% of 75-76 year olds, putting them at increased stroke risk. The preliminary findings of the STROKESTOP trial were presented at the ESC Congress today by Dr Emma Svennberg from Sweden.Stroke is the second cause of death worldwide. Atrial fibrillation is the most common clinically relevant cardiac arrhythmia in Europe, affecting approximately 1.5–2% of the general population.1 Prevalence is estimated to double in the next 50 years as the population ages.Patients with atrial fibrillation have a five-fold increased risk of ischaemic stroke even though around 30% have no symptoms. As blood is less adequately shifted from the heart during atrial fibrillation, blood clots can form and cause large ischaemic strokes. Strokes that occur in association with atrial fibrillation are often fatal, and survivors are left more disabled and at a high risk of a recurrent stroke.
Dr Svennberg said: “There is hope, however, as oral anticoagulant medication reduces the risk of atrial fibrillation related stroke by 64-70%. But more than 50% of high-risk patients with atrial fibrillation do not receive any treatment.2 We are looking at an epidemic of atrial fibrillation related strokes if nothing is done to improve treatment levels.”
The STROKESTOP trial is a mass screening programme of all 75-76 year olds in Stockholm County and Region Halland in Sweden. It aims to identify patients with undiagnosed atrial fibrillation and find out if oral anticoagulation (OAC) therapy reduces their risk of ischaemic stroke.For the trial, more than 25,000 people born in 1936 and 1937 were randomised 1:1 to screening for atrial fibrillation or a control group. Screening is done at home with a handheld ECG device and takes 1 minute per day for 2 weeks. When atrial fibrillation is diagnosed, patients are offered OAC treatment. Both screening and control groups will be followed prospectively for 5 years for thromboembolic events, bleeding and mortality.Preliminary results from STROKESTOP are presented today. A year into the trial, 6,496 (50%) of the 13,000 inhabitants in the screening arm agreed to screening for atrial fibrillation. A lower proportion of patients agreed to screening in Stockholm (49%) than in rural areas (65%). Dr Svennberg said: “We will investigate factors related to participation, in an effort to increase uptake.” More than 11% of the screening group had atrial fibrillation. Of these, previously undiagnosed atrial fibrillation was found in 192 (3%) of patients while in 129 (2%) of patients, atrial fibrillation had been diagnosed but they were not on OAC. More than 90% of the patients with undiagnosed atrial fibrillation were started on OAC.
Dr Svennberg said: “We found that 5% of patients in the screening arm had untreated atrial fibrillation. We successfully started oral anticoagulation treatment in more than 90% of the patients with newly diagnosed atrial fibrillation. This should reduce their risk of a stroke by up to 70%. We are still collecting data on patients with known atrial fibrillation but not on OAC.”
Professor Mårten Rosenqvist, chair of the STROKESTOP steering committee, said: “Without appropriate treatment atrial fibrillation is a ticking bomb. We hope the STROKESTOP study will show that screening for atrial fibrillation reduces the risk of stroke. Our final results should be available by November 2018.”ENDS
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2013. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.More information on the ESC Press Conference page: Heart and Stroke
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2013The ESC Congress is currently the world’s premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information on ESC Congress 2013 contact the ESC Press Office.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved